Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Spark's Gene Therapy Is On The Cusp Of Approval; Now It Gets Interesting

Executive Summary

Spark's Luxturna is all but guaranteed to reach the US market as the first gene therapy following a unanimous positive FDA advisory committee review. Discussions about cost and value are sure to intensify.


Related Content

Spark's Luxturna Approval Ushers In A New Gene Therapy Era
Capacity Shortages Unlikely To Hold Back Cell And Gene Therapies
$1M For Luxturna? ICER Says Big Discount Needed To Be Cost Effective
Spark Stands By $1M Or More Price Possibility For Luxturna
Start-Up Quarterly Statistics: Fundraising Fell, But Deal-Making Rose In Q3
Spark's Gene Therapy Luxturna Sails Through US FDA Panel
Spark's Vision Loss Gene Therapy Raises US FDA Questions About Novel Endpoint
Cornering The Market On Innovation? The First CAR-T And The First Gene Therapy
ICER Eyes Gene Therapy: Category-wide Policy In Works As Spark Moves To Approval
Gene Therapy Reimbursement: Is Blindness A Bad First Test?


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts